Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Centessa Pharmaceuticals in a note issued to investors on Monday, March 24th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings of ($0.37) per share for the quarter. The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals' Q2 2025 earnings at ($0.38) EPS and Q4 2025 earnings at ($0.41) EPS.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04.
Several other brokerages have also issued reports on CNTA. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating on the stock. Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday. Finally, Morgan Stanley reiterated an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of "Buy" and an average price target of $26.00.
Read Our Latest Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Price Performance
Shares of NASDAQ:CNTA traded up $0.08 during midday trading on Wednesday, hitting $14.59. The stock had a trading volume of 620,346 shares, compared to its average volume of 548,232. Centessa Pharmaceuticals has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The company has a market capitalization of $1.92 billion, a P/E ratio of -9.54 and a beta of 1.54. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company's 50-day moving average price is $16.48 and its 200-day moving average price is $16.42.
Insiders Place Their Bets
In related news, insider Gregory M. Weinhoff sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total transaction of $163,400.00. Following the completion of the sale, the insider now owns 134,021 shares of the company's stock, valued at $2,189,903.14. This trade represents a 6.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the transaction, the general counsel now owns 118,265 shares in the company, valued at $1,808,271.85. The trade was a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 260,168 shares of company stock worth $4,309,568. 11.59% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Centessa Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $31,000. GAMMA Investing LLC boosted its holdings in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC grew its stake in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $171,000. 82.01% of the stock is owned by institutional investors.
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Further Reading
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
